Please select the option that best describes you:
Topics:
Breast Cancer • Medical Oncology • NCI-CCC Tumor Board Question • University of Iowa • HR+ • NCI-CCC Breast Tumor Board Question • Breast Cancer, Non-metastatic
Would you still obtain Ki-67 prior to use of adjuvant abemaciclib in a patient who has otherwise met MonarchE treatment criteria, such as 1-3 positive LNs, grade 3 and/or tumor >5 cm?
Patient is pre-menopausal and has cT3cN1, grade 2, ER positive, Her 2 negative IDC. Metastatic disease to axillary LNs was biopsy-proven. Patient was given neoadjuvant ddAC-T with excellent response (ypT1cN0(i+)) post-lumpectomy. Would their response to neoadjuvant chemotherapy affect your decision?
Answer from: Medical Oncologist at Academic Institution
In the setting of a patient with residual disease after NAT with an initial grade 3 stage IIIA ER positive breast cancer, I would treat with adjuvant abemaciclib regardless of Ki67 status if the absolute risk of recurrence was high enough. pCR rates after NAT for ER positive breast cancer are low, a...
Sign in or Register to read more